172 related articles for article (PubMed ID: 32531115)
21. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp.
Smith SR; Morhenn VB; Piacquadio DJ
J Drugs Dermatol; 2006 Feb; 5(2):156-9. PubMed ID: 16485883
[TBL] [Abstract][Full Text] [Related]
22. Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care.
Perino F; Fattori A; Piccerillo A; Bianchi L; Fargnoli MC; Frascione P; Pellacani G; Carbone A; Campione E; Esposito M; Rossi MT; Casari A; Calzavara-Pinton P; Peris K
Ital J Dermatol Venerol; 2022 Apr; 157(2):164-172. PubMed ID: 34282872
[TBL] [Abstract][Full Text] [Related]
23. Using photodynamic therapy to estimate effectiveness of innovative combined diclofenac and tazaroten therapy of disseminated actinic keratosis.
Osiecka BJ; Jurczyszyn K; Nockowski P; Lipinski A; Sieja A; Ziółkowski P
Acta Dermatovenerol Croat; 2015; 23(1):52-8. PubMed ID: 25969914
[TBL] [Abstract][Full Text] [Related]
24. Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses.
Dirschka T; Bierhoff E; Pflugfelder A; Garbe C
J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):258-63. PubMed ID: 19709346
[TBL] [Abstract][Full Text] [Related]
25. Topical treatment of actinic keratosis with 3.0% diclofenac in 2.5% hyaluronan gel: review of the literature about the cumulative evidence of its efficacy and safety.
Javor S; Cozzani E; Parodi A
G Ital Dermatol Venereol; 2016 Jun; 151(3):275-80. PubMed ID: 26512929
[TBL] [Abstract][Full Text] [Related]
26. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
[TBL] [Abstract][Full Text] [Related]
27. Solar keratoses: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies.
Schmitt AR; Bordeaux JS
Clin Dermatol; 2013; 31(6):712-7. PubMed ID: 24160275
[TBL] [Abstract][Full Text] [Related]
28. New and emerging topical approaches for actinic keratoses.
Del Rosso JQ
Cutis; 2003 Oct; 72(4):273-6, 279. PubMed ID: 14604078
[TBL] [Abstract][Full Text] [Related]
29. Topical diclofenac in the treatment of actinic keratoses.
Merk HF
Int J Dermatol; 2007 Jan; 46(1):12-8. PubMed ID: 17214714
[No Abstract] [Full Text] [Related]
30. Diclofenac Sodium 3% in Hyaluronic Acid 2.5% Gel Significantly Diminishes the Actinic Keratosis Area and Severity Index.
Schmitz L; Gupta G; Segert MH; Kost R; Sternberg J; Gambichler T; Stockfleth E; Dirschka T
Skin Pharmacol Physiol; 2018; 31(4):206-211. PubMed ID: 29791916
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of action of new treatment modalities for actinic keratosis.
Berman B; Villa AM; Ramirez CC
J Drugs Dermatol; 2006 Feb; 5(2):167-73. PubMed ID: 16485885
[TBL] [Abstract][Full Text] [Related]
32. A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp.
Zane C; Facchinetti E; Rossi MT; Specchia C; Calzavara-Pinton PG
Br J Dermatol; 2014 May; 170(5):1143-50. PubMed ID: 24506666
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of actinic keratoses using nonthermal atmospheric pressure plasma: A case series.
Friedman PC; Miller V; Fridman G; Lin A; Fridman A
J Am Acad Dermatol; 2017 Feb; 76(2):349-350. PubMed ID: 28088998
[No Abstract] [Full Text] [Related]
34. Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis.
Nisticò S; Del Duca E; Torchia V; Gliozzi M; Bottoni U; Muscoli C
Int J Immunopathol Pharmacol; 2018; 32():2058738418757925. PubMed ID: 29442526
[TBL] [Abstract][Full Text] [Related]
35. Pharmacoeconomy of drugs used in the treatment of actinic keratoses.
Nisticò S; Torchia V; Gliozzi M; Bottoni U; Del Duca E; Muscoli C
Int J Immunopathol Pharmacol; 2016 Dec; 29(4):796-804. PubMed ID: 27207444
[TBL] [Abstract][Full Text] [Related]
36. Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses.
Rivers JK
Skin Therapy Lett; 2004 Jan; 9(1):1-3. PubMed ID: 14716439
[TBL] [Abstract][Full Text] [Related]
37. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
38. Topical 3% diclofenac in 2.5% hyaluronic acid gel: a review of its use in patients with actinic keratoses.
Jarvis B; Figgitt DP
Am J Clin Dermatol; 2003; 4(3):203-13. PubMed ID: 12627996
[TBL] [Abstract][Full Text] [Related]
39. Does progression from actinic keratosis and Bowen's disease end with treatment: diclofenac 3% gel, an old drug in a new environment?
Patel MJ; Stockfleth E
Br J Dermatol; 2007 May; 156 Suppl 3():53-6. PubMed ID: 17488408
[TBL] [Abstract][Full Text] [Related]
40. Assessing clinically meaningful end points for the management of actinic keratosis with diclofenac 3% gel.
Rivers JK; Wolf J
Acta Derm Venereol; 2007; 87(2):188-9. PubMed ID: 17340038
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
